Weekly Recap | BIOCYTOGEN-B -0.72%, consensus target above spotWeekly Review·Nov 14, 2026 at 05:18 AM02315-3.50%
Weekly Recap | BIOCYTOGEN-B +5.86%, consensus target above spotWeekly Review·Nov 7, 2026 at 05:46 AM02315-3.50%
Biocytogen Pharmaceuticals (SEHK:2315) Stock Sinks Despite Profitable Q3 ResultsSimplywall·Oct 30, 2026 at 12:53 PM02315-3.50%688796-2.14%
Biocytogen climbs 6% as CRO leader WuXi AppTec raises guidanceMarket Movers·Oct 28, 2026 at 01:49 AM02315-3.50%
Weekly Recap | BIOCYTOGEN-B -15.58%, a full-week slideWeekly Review·Oct 24, 2026 at 05:19 AM02315-3.50%
Cytogen Extends Equipment Supply Contract Deadline to Dec. 4, 2026PUBT·Oct 20, 2026 at 08:06 AM02315-3.50%
Weekly Recap | BIOCYTOGEN-B -18.88%, a steady one-way pullbackWeekly Review·Oct 17, 2026 at 05:39 AM02315-3.50%